Deferasirox,
Showing 1 - 25 of 114
Transfusion-dependent Thalassemia, Non-transfusion-dependent Thalassemia Trial in Worldwide (Deferasirox dispersable tablet
Completed
- Transfusion-dependent Thalassemia
- Non-transfusion-dependent Thalassemia
- Deferasirox dispersable tablet (DT)
- Deferasirox film coated tablet (FCT)
-
Alexandria, Egypt
- +16 more
Sep 6, 2021
Thalassemia, Iron Overload Trial in Oakland (Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO))
Completed
- Thalassemia
- Iron Overload
- Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)
-
Oakland, CaliforniaCHRCO
Jul 20, 2021
Sickle Cell Disease Trial in Amsterdam (Deferasirox 360 MG)
Recruiting
- Sickle Cell Disease
- Deferasirox 360 MG
-
Amsterdam, Meibergdreef 9, NetherlandsAmsterdan UMC location AMC
May 23, 2022
Cardiac Iron Overload Trial in Worldwide (Deferasirox and Deferoxamine)
Completed
- Cardiac Iron Overload
- Deferasirox and Deferoxamine
-
Toronto, Ontario, Canada
- +14 more
Jul 23, 2021
Beta-thalassemia, Iron Overload Trial in Los Angeles, Oakland, Chicago (Deferasirox)
Completed
- Beta-thalassemia
- Iron Overload
-
Los Angeles, California
- +2 more
Jun 8, 2021
MDS, Iron Overload Trial in Stanford, Detroit, Houston (Deferasirox)
Completed
- Myelodysplastic Syndromes
- Iron Overload
-
Stanford, California
- +2 more
Jun 1, 2021
Transfusional Iron Overload, Iron Overload, Iron Chelation Trial (SPD602, Deferasirox)
Withdrawn
- Transfusional Iron Overload
- +6 more
- (no location specified)
Jun 1, 2021
ß-thalassemia, Transfusional Iron Overload Trial in Cagliari, Genova, Orbassano (Deferasirox)
Completed
- β-thalassemia
- Transfusional Iron Overload
-
Cagliari, CA, Italy
- +2 more
Dec 6, 2020
MDS Trial in Erlangen (Deferasirox (Novartis Pharma))
Terminated
- Myelodysplastic Syndromes
- Deferasirox (Novartis Pharma)
-
Erlangen, Bavaria, GermanyMedizinische Klinik 5, Universitätsklinikum Erlangen
Sep 11, 2020
Chronic Iron Overload Trial in Worldwide (Deferiprone, Deferasirox)
Completed
- Chronic Iron Overload
-
Lushnjë, Albania
- +21 more
Apr 8, 2021
Endocrine Function During Deferasirox Therapy
Completed
- Iron Overload
- +2 more
-
Naples, ItalyUniversità degli Studi della Campania Luigi Vanvitelli
Aug 13, 2020
Anemia, Myelodysplastic Syndrome Trial in Seattle (Deferasirox, Laboratory Biomarker Analysis)
Terminated
- Anemia
- Myelodysplastic Syndrome
- Deferasirox
- Laboratory Biomarker Analysis
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 12, 2020
Myelodysplastic Syndrome, Iron Overload Trial in Canada, United States (Deferasirox)
Completed
- Myelodysplastic Syndrome
- Iron Overload
-
Birmingham, Alabama
- +47 more
Jul 21, 2021
High Risk MDS or AML Patients Trial in Philadelphia (Exjade® (deferasirox, ICL670))
Completed
- High Risk MDS or AML Patients
- Exjade® (deferasirox, ICL670)
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Apr 7, 2020
Acute Myeloid Leukemia Trial in Maywood (Deferasirox, Cholecalciferol, Azacitidine)
Terminated
- Acute Myeloid Leukemia
- Deferasirox
- +2 more
-
Maywood, IllinoisLoyola University Cardinal Bernardin Cancer Center
Feb 25, 2020
Transfusion-dependent ß-thalassemia Patients, Cardiac Iron Overload Trial in Athens, Patras (Deferasirox, Deferoxamine (DFO))
Terminated
- Transfusion-dependent β-thalassemia Patients
- Cardiac Iron Overload
- Deferasirox
- Deferoxamine (DFO)
-
Athens, GR, Greece
- +3 more
Oct 21, 2019
Non-transfusion Dependent Thalassemia Trial in Worldwide (deferasirox)
Completed
- Non-transfusion Dependent Thalassemia
-
Nanning, Guangxi, China
- +10 more
Sep 19, 2019
Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease Trial in Boston (Deferoxamine, Deferasirox, HIDA)
Completed
- Transfusion-dependent Hemachromatosis
- +2 more
- Deferoxamine
- +2 more
-
Boston, MassachusettsChildren's Hospital Boston
Jun 14, 2019
MDS Trial in Worldwide (Deferasirox, Placebo)
Thalassemia Major With Severe Transfusional Iron Overload Trial in Chicago, Philadelphia (Deferasirox and deferiprone)
Completed
- Thalassemia Major With Severe Transfusional Iron Overload
- Deferasirox and deferiprone
-
Chicago, Illinois
- +1 more
Feb 13, 2019